TUBERSOL®,  a product of Sanofi Pasteur Limited, is in shortage nationwide until at least  the end of May 2013. TUBERSOL® is one of two purified-protein derivative (PPD)  tuberculin products that are licensed by the United States Food and Drug  Administration (FDA). The manufacturer notified CDC that 50-dose vials of  TUBERSOL® are unavailable and that the supplies of 10-dose vials will be  limited. This notice advises public health officials, clinicians, and workers  in occupational health and infection control about how to adapt to the  shortage.